A Phase 1 interventional study of AIV001 in Scar, Incision and Abdominal, sponsored by AiViva BioPharma, Inc.. Completed at 2 sites in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by AiViva BioPharma, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 199 studies in Cicatrix with a site in United States — 25 open to participants now, 35 under way, 2 of them phase 3. Cicatrix · United States.
Among the 199 studies in Cicatrix with a site in United States, this one is the 123rd largest by enrollment of the 185 interventional ones that give a count, is one of 9 that started in 2018, is one of 13 in phase 1, and was the 123rd registered.
616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.
Browse Cicatrix studies →25 of the 199 studies in Cicatrix with a site in United States are open now. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
Ages 18+ · Women only
AbbVie · Sites in United States
Ages 22+
University of California, Davis · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.
This study: 21 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
199 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 34 · Phase 3 6 · Phase 4 5
First in 1995; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 40 across 515 interventional studies indexed under Cicatrix.
Median enrollment 25 across the 185 interventional studies, 101 across the 13 observational. Of the 131 that completed or were terminated, 56 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 199 have an industry lead sponsor. The 10 most frequent:
AiViva BioPharma, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
AiViva BioPharma, Inc. has 2 studies filed under Cicatrix — fewer than ten, so there is no comparison to draw.
9 of the studies in Cicatrix with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05478551Phase 3Henry Ford Health SystemRandomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization | 2026-12-30 |
| NCT05758181University of California, DavisUndermining Apices in Surgical Wounds | 2026-12-31 |
| NCT06448481University of California, DavisAesthetic Outcome of Intra-dermal Versus Transcutaneous Purse-string Closure | 2027-01-01 |
| NCT06171386Wake Forest University Health SciencesMicroneedling vs Dermabrasion for Early Facial Scar Resurfacing | 2027-04 |
| NCT06903208Columbia UniversityRFA for Superficial Lipomas | 2027-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 199 studies in Cicatrix with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety, efficacy and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with incisional wounds
This is primarily a safety study to evaluate the safety of AIV001 when administered near incisional wounds. A unique model was used to assess incisional scarring, safety and biomarker assessments. Women electing to have the abdominoplasty procedure were enrolled in the study and abdominal incisions were generated on the abdominal skin. Up to 10 incisions were made on abdominal skn and treated as assigned. And data collection was conducted up to day 49 when the subjects were exited from the study and the abdominoplasty procedure performed. Exploratory efficacy measures were collected and pharmacokinetic profiles determined.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle.
Drug: AIV001
One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle.
Drug: AIV001
One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle.
Drug: AIV001
One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle.
Drug: AIV001
Intradermal injection
Also known as: AIV001 suspension
Adverse events
Local and systemic adverse events
Time frame: Day 1 through Day 49
Efficacy using Patient and Observer Scar Assessment Scale (6 parameters, 1 normal to 10 worst imaginable)
Evaluation of the healing of the wounds
Time frame: Day 7 through 49
Modified Vancouver Scar Scale (4 parameters, 0 = normal to 3 or 4 = severe)
Evaluation of the healing wounds
Time frame: Day 7 through 49
100 mm Visual Analogue Scale (0 = normal to 10 = poor scar)
Evaluation of healing wounds
Time frame: Day 7 through 49
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2018 to primary completion in Dec 2019, 12 months.
Of 16 phase 1 interventional studies under Cicatrix, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 17. This study's 12 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Multi-kinase Inhbitor AIV001
AiViva BioPharma, Inc.